ADMA
ADMA BIOLOGICS, INC.
Next earnings Aug 4, 2026 · consensus $0.18 EPS, $135M rev
Last earnings -1.7% on 2026-05-06
$8.75
▲ +0.34%$8.75▼ -51.04%
over 1Y
L $7.60EODHDH $20.38
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.3%
1W+2.1%
1M+10.5%
3M-5.4%
YTD-51.1%
1Y-51.0%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Revenue grew 19.6% YoY.
Revenue (FY2025) $510M · FY2025
The read
The fundamentals carry the rating, but the price is rich (~33% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
ADMA BIOLOGICS, INC. shows $510M in FY2025 revenue (+19.6% YoY), a 28.8% net margin, and 30.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $80.9M | $154M | $258M | $426M | $510M |
| Gross profit | $1.17M | $35.3M | $88.9M | $220M | $293M |
| Operating income | -$58.4M | -$39.4M | $21.6M | $139M | $191M |
| Net income | -$71.6M | -$65.9M | -$28.2M | $198M | $147M |
| Diluted EPS | -$0.51 | -$0.33 | -$0.13 | $0.81 | $0.60 |
| Net margin | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.07B
EV / EBITDA10.4
EV / Sales4.1
EV / FCF74.3
P / FCF74.9
PEG (trailing)—
Earnings yield7.1%
FCF yield1.3%
Quality & risk
ROIC (est.)27.5%
Free cash flow$27.8M
Total debt$72.1M
Net cash$15.5M
Altman Z-Score10.74 safe
Piotroski F-Score5/9
Capital returns
Buyback yield1.5%
Dividend yield (est.)—
Shareholder yield1.5%
Shares Δ YoY+0.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-022026-06-02open ↗4Period ending 2026-05-272026-05-28open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-112026-05-12open ↗10-QPeriod ending 2026-03-312026-05-06open ↗8-KPeriod ending 2026-05-062026-05-06open ↗8-KPeriod ending 2026-05-042026-05-04open ↗SCHEDULE 13GFiling2026-04-29open ↗ARSPeriod ending 2025-12-312026-04-15open ↗DEFA14AFiling2026-04-15open ↗DEF 14APeriod ending 2026-06-022026-04-15open ↗4Period ending 2026-04-012026-04-03open ↗
Frequently asked
- Is ADMA BIOLOGICS, INC. (ADMA) a buy?
- ADMA currently carries a Buy rating with 5/5 conviction, derived from its latest SEC filings. Revenue grew 19.6% YoY.
- What is ADMA's fair value?
- A Modified-Graham model based on ADMA's SEC fundamentals estimates a fair value of about $5.89. It is an estimate from reported earnings, not a price target.
- Is ADMA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, ADMA currently appears overvalued relative to its SEC-grounded earnings power.
- What is ADMA BIOLOGICS, INC.'s quality score?
- ADMA scores 75.62745098039214/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001368514, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 5:56:43 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.